ClearSphere

ClearSphere is a biotechnology company specializing in the discovery of small molecules that modulate protein stability via the ubiquitin-proteasome system (UPS). Utilizing its proprietary ClearSphere™ platform, the company identifies novel chemical entities that can either induce the degradation of disease-causing proteins or stabilize beneficial ones that are deficient. The technology is designed to address "undruggable" targets across various therapeutic areas, including oncology and neurodegeneration, by leveraging high-throughput flow cytometry and advanced computational modeling. ClearSphere originated as a spin-out from the University of New Mexico and is led by experts in drug discovery and informatics.